Eli Lilly announced it will present important clinical trial data at the 2026 ASCO Annual Meeting, including Phase 3 results for Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive non-small cell lung cancer and Verzenio (abemaciclib) in advanced dedifferentiated liposarcoma. Additional presentations cover investigational therapies like an antibody-drug conjugate targeting Nectin-4 and Kelonia Therapeutics' in vivo CAR-T therapy for multiple myeloma. These findings highlight Lilly's expanding oncology portfolio and ongoing commitment to innovative cancer treatments. The data presentations are expected to influence future cancer treatment approaches and regulatory decisions.
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
Eli Lilly reported positive Phase 3 trial results for retatrutide, a triple hormone drug targeting obesity. Patients on the highest 12 mg dose lost an average of 28.3% of their body weight, with significant improvements in cardiovascular risk markers...
Eli Lilly reported a 55.5% revenue increase in Q1 2026, driven by strong sales of Mounjaro and Zepbound. Despite this growth and raised full-year guidance, shares have fallen due to pricing pressures from China and the U.S., and competition from Novo...
Eli Lilly's next-generation obesity drug, retatrutide, achieved significant weight loss in a late-stage trial, with patients losing up to 28.3% of their body weight over 80 weeks. The drug, which targets three gut hormones, outperformed existing trea...
Incyte has signed a $120 million partnership with Genesis Molecular AI, including $80 million upfront and a $40 million equity investment, to advance AI-driven drug discovery. This deal could exceed $1 billion with future milestones and royalties, us...
